AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01460966 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Filtrap™ + Thrombus aspiration catheter
Description: Combination of distal protection device (Filtrap™ )and thrombus aspiration catheter
Study NCT01460966 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thrombus aspiration catheter
Description: Thrombus aspiration catheter only
Study NCT02121379 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pulmonary rehabilitation
Study NCT04199507 — intervention group
Intervention type: OTHER
Intervention: physical fitness assessment
Description: assessment
Study NCT04368260 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control swab
Description: FDA-cleared nasopharyngeal swab
Study NCT04368260 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype swab
Description: Injection molded polypropylene flocked nylon nasopharyngeal swab
Study NCT02906423 — intervention group
Intervention type: OTHER
Intervention: PROMIS-10 questionnaire
Description: Patient completed a PROMIS-10 questionnaire
Study NCT02232035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: normal saline/diazepam at the active phase of labor
Description: A single dose intravenous injection of normal saline (2ml)/diazepam (10mg, 2ml) at the beginning of active phase of labor.
Study NCT02232035 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline/diazepam at the active phase of labor
Description: A single dose intravenous injection of normal saline (2ml)/diazepam (10mg, 2ml) at the beginning of active phase of labor.
Study NCT01009658 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Monosodium glutamate
Description: Oral intake of 2.0 g of monosodium glutamate on the examination day and 0.6 g of sodium chloride on the other examination day.
Study NCT01009658 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: Oral intake of 0.6 g of sodium chloride on the examination day and 2.0 g of monosodium glutamate on the other examination day.
Study NCT02760615 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Caffeine
Description: Caffeine tablets
Study NCT02760615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Caffeine tablets
Study NCT02760615 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Losartan
Description: Losartan tablets
Study NCT02760615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan tablets
Study NCT02760615 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Omeprazole
Description: Omeprazole capsules
Study NCT02760615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole capsules
Study NCT02760615 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dextromethorphan
Description: Dextromethorphan capsules
Study NCT02760615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: Dextromethorphan capsules
Study NCT02760615 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam
Description: Midazolam syrup
Study NCT02760615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam syrup
Study NCT02760615 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vedolizumab
Description: Vedolizumab solution for IV infusion
Study NCT02760615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab solution for IV infusion
Study NCT01274026 — intervention group
Intervention type: DRUG
Intervention: sapropterin dihydrochloride
Description: In 30 PKU patients found previously to exhibit no decrease in blood PHE levels behavioral and cognitive function, neurotransmitter levels, and gene expression of enzyme activity will be measured at baseline and after 4 weeks of Kuvan administration. Rating inventories of executive function performance and behavior will be administered to patients and parents.~Urine neurotransmitters, blood microarray expression, and plasma amino acids will be measured (plasma PHE and TYR levels will also be measured at weeks 1 and 2). Nutrient analysis of 3 day food diaries will be conducted.
Study NCT00734435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zonisamide SR plus olanzapine
Description: zonisamide SR 90 mg given twice daily and olanzapine 10 mg to 20 mg daily for 10 weeks (maintenance period)
Study NCT00734435 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus olanzapine
Description: Placebo given twice daily and olanzapine 10-20 mg for 10 weeks (maintenance period)
Study NCT04203511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: INCMGA00012 administered intravenously every 3 weeks on Day 1 of each 21-day cycle for 4 cycles, followed by a consolidation part of INCMGA00012 administered intravenously on Day 1 of each 28-day cycle for up to12 cycles.
Study NCT04203511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo administered intravenously every 3 weeks on Day 1 of each 21-day cycle for 4 cycles, followed by a consolidation part of placebo administered intravenously on Day 1 of each 28-day cycle for up to 12 cycles.
Study NCT04203511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed administered intravenously every 3 weeks on Day 1 of each cycle with either carboplatin or cisplatin (nonsquamous NSCLC only) for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
Study NCT04203511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed administered intravenously every 3 weeks on Day 1 of each cycle with either carboplatin or cisplatin (nonsquamous NSCLC only) for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
Study NCT04203511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin administered intravenously every 3 weeks on Day 1 of each cycle with either etoposide or pemetrexed (nonsquamous NSCLC only) for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
Study NCT04203511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin administered intravenously every 3 weeks on Day 1 of each cycle with either etoposide or pemetrexed (nonsquamous NSCLC only) for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
Study NCT04203511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin administered intravenously every 3 weeks on Day 1 of each cycle with either pemetrexed (nonsquamous NSCLC only) or paclitaxel for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
Study NCT04203511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin administered intravenously every 3 weeks on Day 1 of each cycle with either pemetrexed (nonsquamous NSCLC only) or paclitaxel for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
Study NCT04203511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel administered intravenously every 3 weeks on Days 1, 8, and 15 of each cycle with carboplatin for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
Study NCT04203511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel administered intravenously every 3 weeks on Days 1, 8, and 15 of each cycle with carboplatin for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
Study NCT04203511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide administered intravenously every 3 weeks on Days 1-3 of each cycle with cisplatin for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
Study NCT04203511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide administered intravenously every 3 weeks on Days 1-3 of each cycle with cisplatin for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
Study NCT04203511 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Total dose of 60 Gy ± 10% (54 to 66 Gy) in 2 Gy daily fractions.
Study NCT04203511 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Total dose of 60 Gy ± 10% (54 to 66 Gy) in 2 Gy daily fractions.
Study NCT00961311 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention
Description: Balloon angioplasty of a severely stenotic coronary lesion with the Sprinter Legend 1.25mm Balloon.
Study NCT00961311 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sprinter Legend 1.25mm Balloon Catheter
Description: Balloon Angioplasty
Study NCT02028923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine gel
Description: Topical
Study NCT02028923 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Neutral gel
Description: Topical
Study NCT02571114 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Saskatoon Berry Frozen Yogurt
Description: Frozen yogurt containing a defined amount of powder prepared from Saskatoon berries (serving size = 25 g available carbohydrate)
Study NCT02571114 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Frozen Yogurt
Description: Unflavoured frozen yogurt (serving size = 25 g available carbohydrate)
Study NCT02571114 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control 1
Description: White bread (serving size = 25 g available carbohydrate)
Study NCT03744104 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine
Description: 0.5 mL, intramuscular, one dose
Study NCT03744104 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent influenza vaccine A
Description: 0.5 mL, intramuscular, one dose
Study NCT02571114 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control 2
Description: White bread (serving size = 25 g available carbohydrate)
Study NCT03223402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nevirapine plus lamivudine
Description: In this Pilot study, the efficacy of a bi-therapy consisting of NVP+3TC instead of NVP+2NRTI should be evaluated before a large multicenter study evaluating this combination is started.
Study NCT03093896 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: snack mix
Description: commercial cereal mix with bits of beef jerky and coconut
Study NCT03093896 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: almonds, 1.5 oz
Description: almonds, 1.5 oz/day
Study NCT03093896 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: almonds, 3 oz
Description: almonds, 3.0 oz/day
Study NCT02212808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antimicrobial restriction
Description: All prescriptions for targeted antibiotics will require phone approval by the trained PharmD during this arm. Prescribers will be instructed to contact the pharmacist via pager or phone call to discuss the patient details and the rationale for the desired antimicrobial. The pharmacist will then decide if the targeted antibiotic is approved or denied. If the pharmacist denies the use of the targeted antibiotic, the pharmacist will provide recommendations for alternative antibiotics for the specific clinical scenario. The pharmacist will document this interaction in the REDCap database.
Study NCT02212808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-antimicrobial prescription review
Description: All prescriptions for targeted antibiotics will be reviewed by the study pharmacist approximately 72 hours after initially written. The pharmacist will review and document the patient's current symptoms, pertinent clinical data, and the indication for the targeted antibiotic documented in the chart. Based on this review, the pharmacist will decide if the targeted antibiotic is necessary and/or if it needs to be modified. If a change is recommended, the pharmacist will then contact the prescriber to discuss the pharmacist's recommendations. The interaction will be documented in the REDCap database.
Study NCT01216202 — intervention group
Intervention type: RADIATION
Intervention: Preoperative radiotherapy
Description: Preoperative radiotherapy (RT) was administered as either short course (5Gy x5) or long-course (2Gy x25 or 1.8 Gy x25 with or without 3 fractions of boost to the primary tumor and radiologically malignant lymph nodes) treatment with or without concomitant or sequential chemotherapy. Oncological treatment was decided at a multidisciplinary team conference.~Testicular doses (TDs) was calculated from planning CT-scans and reported as mean cumulative testicular dose. Relative TD was calculated based in the assumption that RT regimens for rectal cancer are bioequivalent and referred to as proportion of prescribed dose absorbed by the testes.
Study NCT02246725 — intervention group
Intervention type: OTHER
Intervention: Contact with palliative care unit.
Study NCT02967146 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: adhesive barrier
Description: After having axillary dissection, investigator has to inject the mediclore on op site directly and suture the site.
Study NCT02519439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ganaxolone
Description: 225 mg capsules 450 mg to 900 mg 2x/day
Study NCT00230126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib
Description: Arm A: 150 mg/day cycles 1 - 3. Arm B: Cycle 1 - 175 or 200 mg/day depending on body weight; Cycle 2 - if rash developed, then 150 mg/day; if no rash, then 175 mg/day; Cycle 3 - if rash developed, then 175 mg/day; if no rash, then 200 mg/day.
Study NCT00230126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: Arm A: 150 mg/day cycles 1 - 3. Arm B: Cycle 1 - 175 or 200 mg/day depending on body weight; Cycle 2 - if rash developed, then 150 mg/day; if no rash, then 175 mg/day; Cycle 3 - if rash developed, then 175 mg/day; if no rash, then 200 mg/day.
Study NCT00434226 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bevacizumab
Description: Intravenously at a dose of 15mg/kg on the first day of each 21-day cycle
Study NCT00434226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Intravenously at a dose of 15mg/kg on the first day of each 21-day cycle
Study NCT00434226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: 25 mg/day for 2 weeks, followed by 1 week of rest
Study NCT00434226 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin
Description: On the first day of each cycle for 4 cycles
Study NCT00434226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: On the first day of each cycle for 4 cycles
Study NCT00434226 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paclitaxel
Description: On the first day of each cycle for 4 cycles
Study NCT00434226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: On the first day of each cycle for 4 cycles
Study NCT03287401 — intervention group
Intervention type: DEVICE
Intervention: Electroencephalography
Description: Patients electroencephalogram will be recorded
Study NCT03901495 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaana
Description: Diaana, the AMHTD used, functions as follows: on the basis of an interactive questionnaire completed by the patient before the consultation, it performs an exhaustive anamnesis focused on the problem and proposes a panel of DDs with a high sensitivity. The artificial reasoning system of Diaana mimics how a specialist physician would reason to establish a DD. The information transmitted is in an easy-to-use form for the physician that includes a summary of the anamnesis centered on relevant elements from the questionnaire and a list of possible diagnoses with their emergency level, potential contributing factors, and first-line management proposals.
Study NCT02223780 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: early palliative care
Description: the patients will benefit from an early palliative care consultation
Study NCT02223780 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: early palliative care
Description: the patients will benefit from an early palliative care consultation
Study NCT03121859 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neck stabilization exercise
Description: Exercise
Study NCT03121859 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: Transcutaneous electrical nerve stimulation (TENS)
Study NCT03121859 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IFC
Description: Interferential current therapy(IFC)
Study NCT03476200 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: The intervention consist of 14 weekly group meetings lasting 1.5 or 2 h. Groups are made up of 10 patients. Each group session follow a structured format and consisted of the following elements: introduction to the session, discussion of homework, group discussion and the development of new coping skills. The sessions deal with the following: concept of stress, cognitive restructuring, alternative thought control strategies, relaxation techniques, training in social skills, training in social skills and humour and optimism as coping strategies.
Study NCT04103359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiological tests to measure fatigue level
Description: Physiological tests to measure fatigue level
Study NCT01319981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: In CD20-positive patients, 375 mg/m2 by vein on day 1 and 8 for Courses 1 and 3; and day 1 and 8 of Courses 2 and 4.
Study NCT01319981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: 600 mg by mouth daily days 1-14 for course 1 and continuously on all other courses for patients who are Philadelphia chromosome positive (Ph+).
Study NCT01319981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 mg/m2 by vein over 3 hours every 12 hours x 6 doses days 1, 2, 3 (total dose 1800 mg/m2) for courses 1, 3, 5, 7
Study NCT01319981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m2 by vein over 24 hours on day 4 after last dose of Cyclophosphamide for courses 1, 3, 5, 7
Study NCT01319981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: 600 mg/m2 by vein continuous infusion daily for 24 hours days 1-3 for courses 1, 3, 5, 7
Study NCT01319981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VSLI
Description: 2.0 mg/m2 by vein on day 1 and day 8 for courses 1, 3, 5, 7
Study NCT01319981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solu-Medrol
Description: 40 mg by vein every 12 hours for 6 doses days 1-3 for courses 2, 4, 6, 8.
Study NCT01319981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 200 mg/m2 IV over 2 hrs followed by 800 mg/m2 over 22 hrs on day 1 beginning after the completion of rituximab for Courses 2, 4, 6, and 8.
Study NCT01319981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: 3 gm/m2 by vein over 2 hours every 12 hours for 4 doses on days 2, 3 for Courses 2, 4, 6, and 8.
Study NCT01319981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 10 µg/kg/day (rounded) given subcutaneously until neutrophil recovery to 1 x 10\^9/L or higher can be substituted or can be added if neutrophils have not recovered to 1 x 10\^9/L by day 21.
Study NCT01319981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: 6 mg/kg (rounded) within 72 hrs after completion of chemotherapy.
Study NCT01319981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg by vein or by mouth daily days 1-4 and days 11-14 for courses 1, 3, 5, 7
Study NCT02367508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MODEL Care
Description: The Mindfully Optimizing Delivery of End-of-Life Care (MODEL Care) intervention is two-pronged and mutually interactive with: (1) a patient and family caregiver group, and (2) an oncology provider group. Patients and family caregivers meet as a group for 6 weekly sessions of 2 hours each, for a total of 12 hours of class time. Oncology providers will have 5 class sessions for a total of 16 hours of class time. One class is held conjointly with patients, family caregivers, and providers to practice newly-learned skills. The course curriculum is generally based on mindfulness practices, group discussion, and didactic teaching with an emphasis on embodying interpersonal mindfulness in dialogue in daily life.
Study NCT00737646 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual care
Description: No intervention will be conducted in this arm of the study.